Cargando…
Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an established role in disease prognostication, particularly in guiding decisions for hematopoietic cell transplantation in first remission. Serial MRD assessment is now routinely recommended in the evaluation of treatm...
Autores principales: | Tiong, Ing S., Loo, Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003715/ https://www.ncbi.nlm.nih.gov/pubmed/36902217 http://dx.doi.org/10.3390/ijms24054790 |
Ejemplares similares
-
Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022) -
P532: KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.
por: Jimenez-Vicente, Carlos, et al.
Publicado: (2023) -
P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023) -
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
por: Li, Yonghong, et al.
Publicado: (2023) -
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)